JP2019532105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532105A5 JP2019532105A5 JP2019541893A JP2019541893A JP2019532105A5 JP 2019532105 A5 JP2019532105 A5 JP 2019532105A5 JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019532105 A5 JP2019532105 A5 JP 2019532105A5
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- dry eye
- severe dry
- surgery
- treating severe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012530 fluid Substances 0.000 claims 30
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 15
- 206010013774 Dry eye Diseases 0.000 claims 15
- 239000003755 preservative agent Substances 0.000 claims 15
- 238000001356 surgical procedure Methods 0.000 claims 12
- 230000002335 preservative effect Effects 0.000 claims 8
- 239000012867 bioactive agent Substances 0.000 claims 6
- 239000003599 detergent Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 210000000170 cell membrane Anatomy 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 229920002413 Polyhexanide Polymers 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 229940124447 delivery agent Drugs 0.000 claims 2
- 239000006196 drop Substances 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940009662 edetate Drugs 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- -1 haptens Substances 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 125000005430 oxychloro group Chemical group 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229940010747 sodium hyaluronate Drugs 0.000 claims 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022122165A JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2024209810A JP2025029084A (ja) | 2016-10-14 | 2024-12-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408559P | 2016-10-14 | 2016-10-14 | |
| US62/408,559 | 2016-10-14 | ||
| US201762516911P | 2017-06-08 | 2017-06-08 | |
| US62/516,911 | 2017-06-08 | ||
| PCT/IB2017/001364 WO2018069763A1 (en) | 2016-10-14 | 2017-10-02 | Method for establishing, restoring, and preserving homeostasis of the ocular surface |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122165A Division JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2024209810A Division JP2025029084A (ja) | 2016-10-14 | 2024-12-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532105A JP2019532105A (ja) | 2019-11-07 |
| JP2019532105A5 true JP2019532105A5 (cg-RX-API-DMAC10.html) | 2020-11-12 |
Family
ID=60766004
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541893A Pending JP2019532105A (ja) | 2016-10-14 | 2017-10-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2022122165A Pending JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2024209810A Pending JP2025029084A (ja) | 2016-10-14 | 2024-12-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122165A Pending JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2024209810A Pending JP2025029084A (ja) | 2016-10-14 | 2024-12-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190240251A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3525799B1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2019532105A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20190068575A (cg-RX-API-DMAC10.html) |
| ES (1) | ES2909998T3 (cg-RX-API-DMAC10.html) |
| HU (1) | HUE058672T2 (cg-RX-API-DMAC10.html) |
| PL (1) | PL3525799T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018069763A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2909998T3 (es) * | 2016-10-14 | 2022-05-11 | I Com Medical Gmbh | Método para establecer, restablecer y preservar la homeostasis de la superficie ocular |
| US12303527B2 (en) | 2018-04-18 | 2025-05-20 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| EP3852725A4 (en) * | 2018-09-20 | 2022-08-03 | The Hong Kong University of Science and Technology | EYE DROP COMPOSITIONS |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| JP2023530286A (ja) * | 2020-06-12 | 2023-07-14 | アイ．コム メディカル ゲーエムベーハー | 角膜神経損傷又は喪失の治療に使用する高分子量ヒアルロン酸 |
| ES3008008T3 (en) * | 2020-06-21 | 2025-03-21 | I Com Medical Gmbh | Use of high molecular weight hyaluronic acid as ocular transporting vehicle |
| EP4536189A4 (en) * | 2022-06-08 | 2026-07-29 | The Schepens Eye Research Inst Inc | METHODS OF TREATING DRY EYE DISEASE |
| EP4591860A1 (en) * | 2024-01-23 | 2025-07-30 | FB Vision S.p.A. | Ophthalmic pharmaceutical composition for the prevention and treatment of dry eye syndrome |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1263606A (en) * | 1985-05-29 | 1989-12-05 | Jeffrey P. Gilbard | Non-toxic opthalmic preparations |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| JP3050898B2 (ja) * | 1990-07-06 | 2000-06-12 | 千寿製薬株式会社 | 水性医薬製剤 |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| IT1277707B1 (it) * | 1995-12-22 | 1997-11-11 | Chemedica Sa | Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare |
| SE9700827D0 (sv) * | 1997-03-07 | 1997-03-07 | Pharmacia & Upjohn Ab | Ophthalmic composition |
| PT1142566E (pt) * | 2000-04-07 | 2004-02-27 | Medidom Lab | Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80 |
| JP2002193815A (ja) * | 2000-12-25 | 2002-07-10 | Ophtecs Corp | 眼手術用角膜乾燥防止点眼剤 |
| US6528464B1 (en) * | 2001-08-17 | 2003-03-04 | Bausch & Lomb Incorporated | Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels |
| JP3779200B2 (ja) * | 2001-11-28 | 2006-05-24 | 電気化学工業株式会社 | ヒアルロン酸及び／又はその塩の水溶液の安定化組成物 |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| EP1455750B1 (en) * | 2001-12-21 | 2006-02-08 | Alcon, Inc. | Viscoelastic ophthalmic compositions comprising hyaluronic acid and chondroitin sulphate |
| US20060094643A1 (en) * | 2002-07-03 | 2006-05-04 | Yuri Svirkin | Compositions of hyaluronic acid and methods of use |
| DE10360425A1 (de) | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung |
| US20080306022A1 (en) * | 2005-10-12 | 2008-12-11 | Kenji Miyamoto | Agent for Applying to Mucosa and Method for the Production Thereof |
| JP2007145765A (ja) * | 2005-11-29 | 2007-06-14 | Menicon Co Ltd | 眼科手術用組成物 |
| JP2008255061A (ja) * | 2007-04-06 | 2008-10-23 | Shiseido Co Ltd | 可溶性架橋ヒアルロン酸含有眼用組成物 |
| EP2187900B1 (en) * | 2007-08-16 | 2016-11-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| CA2724052A1 (en) * | 2008-05-15 | 2009-11-19 | R-Tech Ueno, Ltd. | Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion |
| JP5595206B2 (ja) * | 2009-09-30 | 2014-09-24 | ロート製薬株式会社 | 眼科用液体組成物 |
| US8283463B2 (en) * | 2010-02-09 | 2012-10-09 | Bausch & Lomb Incorporated | Sterile hyaluronic acid solutions |
| HRP20230776T1 (hr) * | 2010-07-29 | 2023-10-27 | Buzzard Pharmaceuticals AB | Himerni antagonisti receptora il-1 tipa i |
| CA2810481C (en) * | 2010-09-10 | 2018-06-19 | Santen Pharmaceutical Co., Ltd. | Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof |
| SG11201703572SA (en) * | 2014-12-02 | 2017-05-30 | Regeneron Pharma | Animal model for dry eye and methods of use of such animals |
| TW202114648A (zh) * | 2015-03-06 | 2021-04-16 | 日商參天製藥股份有限公司 | 眼科用組成物 |
| US20170014339A1 (en) | 2015-07-17 | 2017-01-19 | i.com medical GmbH | Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute |
| ES2909998T3 (es) | 2016-10-14 | 2022-05-11 | I Com Medical Gmbh | Método para establecer, restablecer y preservar la homeostasis de la superficie ocular |
| US12303527B2 (en) * | 2018-04-18 | 2025-05-20 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| US12268706B2 (en) * | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
-
2017
- 2017-10-02 ES ES17817868T patent/ES2909998T3/es active Active
- 2017-10-02 WO PCT/IB2017/001364 patent/WO2018069763A1/en not_active Ceased
- 2017-10-02 JP JP2019541893A patent/JP2019532105A/ja active Pending
- 2017-10-02 PL PL17817868T patent/PL3525799T3/pl unknown
- 2017-10-02 EP EP17817868.7A patent/EP3525799B1/en not_active Revoked
- 2017-10-02 HU HUE17817868A patent/HUE058672T2/hu unknown
- 2017-10-02 US US16/341,915 patent/US20190240251A1/en active Pending
- 2017-10-02 KR KR1020197013278A patent/KR20190068575A/ko not_active Ceased
- 2017-10-02 EP EP21167346.2A patent/EP3871682A1/en active Pending
-
2022
- 2022-07-29 JP JP2022122165A patent/JP2022153583A/ja active Pending
-
2024
- 2024-12-02 JP JP2024209810A patent/JP2025029084A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230404961A1 (en) | Ophthalmic compositions and methods for treating eyes | |
| CN111991415B (zh) | 一种眼部护理组合物及其制备方法和用途 | |
| CA2630193C (en) | Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator | |
| WO2020140365A1 (zh) | 一种含有黄原胶的保湿润滑组合物及其应用 | |
| US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
| US7820639B2 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| US20070141091A1 (en) | Biguanide ointment and method of treatment and prevention of infections | |
| US9233123B1 (en) | Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan | |
| JP2023038930A (ja) | 眼表面薬物滞留化剤およびこれを含む点眼剤、並びに、これらの剤を用いた眼表面薬物滞留方法および眼科疾患治療方法 | |
| US8551974B1 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| KR101723703B1 (ko) | 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물 | |
| JP2008189677A (ja) | 洗浄剤 | |
| WO2021101883A1 (en) | Chitosan containing compositions and methods relating to same | |
| US20250302868A1 (en) | Hypochlorous acid-based dry eye formulations | |
| CN102727874B (zh) | 重组水蛭素滴眼液及其制备方法 | |
| KR20220008720A (ko) | 카라기난을 포함하는 점안용 조성물 | |
| JP5957517B2 (ja) | 結膜弛緩症治療用の点眼薬 | |
| JP2019514887A (ja) | グリコーゲンとヒアルロン酸またはその塩との相乗的組み合わせを含む眼科用組成物 | |
| CN118526516A (zh) | 一种高渗透性的隐形眼镜护理液及其制备方法 | |
| JPWO2000028998A1 (ja) | 眼用液剤 | |
| HK1125027B (en) | Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator | |
| JP2004043516A (ja) | 眼科用剤 |